

1 **Enhanced Gut Microbiome Capacity for Amino Acid Metabolism is associated with**
2 **Peanut Oral Immunotherapy Failure**

3
4 Mustafa Özçam¹, Din L. Lin¹, Chhedi L. Gupta^{1,2,#}, Allison Li¹, Lisa M. Wheatley³, Carolyn H.
5 Baloh^{4,5,6}, Srinath Sanda⁷, Stacie M. Jones⁸, Susan V. Lynch^{1*}
6
7

8 ¹Division of Gastroenterology, Department of Medicine, University of California, San Francisco,
9 San Francisco, CA, USA

10 ²Benioff Center for Microbiome Medicine, Department of Medicine, University of California, San
11 Francisco, San Francisco, CA, USA

12 ³National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda,
13 MD, USA.

14 ⁴The Immune Tolerance Network, Boston, MA, USA

15 ⁵Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, MA,
16 USA

17 ⁶Harvard Medical School, Boston, MA, USA

18 ⁷The Immune Tolerance Network, San Francisco, CA, USA

19 ⁸Division of Allergy and Immunology, Department of Pediatrics, University of Arkansas for
20 Medical Sciences and Arkansas Children's Hospital, Little Rock, AR, USA

21
22 #Present Address: ICMR-National Institute of Immunohaematology, Chandrapur Unit
23 (ICMR-CRMCH), Maharashtra, India

24
25 *Corresponding author: susan.lynch@ucsf.edu

26
27 **Abstract**

28
29 Peanut Oral Immunotherapy (POIT) holds promise for remission of peanut allergy, though
30 treatment is protracted and successful in only a subset of patients. Because the gut microbiome
31 is linked to food allergy, we sought to identify fecal microbial predictors of POIT efficacy and to
32 develop mechanistic insights into treatment response. Longitudinal functional analysis of the fecal
33 microbiome of children (n=79) undergoing POIT in a first double-blind, placebo-controlled clinical
34 trial, identified five microbial-derived bile acids enriched in fecal samples prior to POIT initiation
35 that predicted treatment efficacy (AUC 0.71). Failure to induce disease remission was associated
36 with a distinct fecal microbiome with enhanced capacity for bile acid deconjugation, amino acid
37 metabolism, and increased peanut peptide degradation *in vitro*. Thus, microbiome mechanisms
38 of POIT failure appear to include depletion of immunomodulatory secondary bile and amino acids
39 and the antigenic peanut peptides necessary to promote peanut allergy desensitization and
40 remission.
41

42
43 **Keywords.** Peanut Allergy, Oral Immunotherapy, Gut Microbiome, Metabolome, Bile Acids.

44 **Main**

45 Peanut protein allergy (PA) is a life-threatening condition affecting 2% of the population in
46 industrialized nations¹. A leading cause of food-induced anaphylaxis², the condition was not
47 treatable until the approval of peanut oral immunotherapy (PalforziaTM) by the U.S. Food and Drug
48 Administration in 2020, with strict avoidance of peanuts and peanut-containing products
49 representing the most effective disease management strategy³. Peanut oral immunotherapy
50 (POIT) has emerged as a treatment that is widely utilized for PA⁴. Gradual oral introduction of
51 increasing concentrations of peanut product induces desensitization, defined as an increase in
52 reaction threshold while on treatment, in approximately 50-70% of treated patients. While POIT
53 has demonstrated efficacy in desensitizing patients to peanut, the induction of remission, defined
54 as the prolonged absence of clinical reactivity after treatment cessation, is observed in a smaller
55 subset of approximately 20-30% of POIT-treated patients⁴⁻⁶. The cost, prolonged duration (years),
56 and burden of daily treatment associated with POIT highlight the need for improved predictive
57 biomarkers and adjunctive treatments to increase efficacy.

58
59 The IMPACT, Oral Immunotherapy for the Induction of Tolerance and Desensitization in
60 Peanut-Allergic Children trial (NCT01867671) was the first randomized, double-blinded, placebo-
61 controlled, multicenter clinical trial to evaluate the efficacy and safety of POIT in peanut-allergic
62 children ages 12-48 months old. While 71% of the children receiving POIT achieved
63 desensitization, only 21% of children achieved remission following POIT discontinuation and 26-
64 weeks of peanut avoidance. The IMPACT trial yielded three clinical outcomes among peanut-
65 allergic children treated with POIT: **i**) those who achieved both desensitization and remission
66 (D+R+), **ii**) those who achieved only desensitization but not remission (D+R-), **iii**) those who did
67 not achieve desensitization or remission (D-R-). Notably, younger age and lower peanut-specific
68 serum IgE concentrations at the outset of the trial were more likely to result in a D+R+ outcome⁷.
69 Both age⁸ and allergic sensitization status⁹ are closely related with early life gut microbiome
70 composition and metabolic activity¹⁰. Thus, we hypothesized that gut microbiome functional
71 features at baseline are associated with both POIT-induced clinical outcomes and peanut IgE
72 levels, and that longitudinal assessment of fecal microbiomes from children in this trial would
73 reveal mechanisms underlying variance in POIT efficacy.

74 **Results**

75 **Study Population and Clinical Trial Outcomes**

76
77
78
79 Details of the IMPACT trial design and outcomes have been published previously⁷. Briefly,
80 at baseline, 146 peanut-allergic children were randomized (2:1) to either POIT or placebo
81 treatment. After a dose escalation phase of 30-weeks, children in the POIT arm received 2,000
82 mg peanut protein (lightly roasted, partly defatted [12% fat]) while the placebo group received oat
83 flour for 104 weeks (total blinded treatment period 134 weeks). Participants who passed the 5-g
84 peanut protein, double-blind, placebo-controlled, food challenge (DBPCFC) at the end of
85 treatment (week 134) were categorized as desensitized (D+). Independent of the DBPCFC
86 outcome at week 134, all participants avoided peanut consumption for 24 weeks (avoidance
87 period), and those who passed the 5-g peanut protein DBPCFC at the end of this avoidance

88 period (week 160) were categorized as being in remission (R+). A total of 327 longitudinal fecal
89 samples from 79 participants (Table S1) were collected at baseline (prior to POIT initiation), end
90 of buildup (EoB), mid maintenance (MM), end of treatment (EoT), and the end of avoidance (EoA
91 **Fig. 1A; Table S1**). Participant baseline characteristics including age, sex and study locations
92 are reported in **Table S2**. Based on DBPCFC results at the end of treatment and end of
93 avoidance, the IMPACT clinical trial yielded three outcome groups, Desensitized and Remission
94 (D+R+), Desensitized and no remission (D+R-) and no desensitization and no remission (D-R-;
95 **Fig. 1A**).

96

97 **Gut microbiota composition associates with peanut oral immunotherapy outcomes.**

98

99 The subgroup of IMPACT trial participants analyzed in our study (n=79 of 146) did not
100 differ in age between POIT and placebo-treated groups (**Extended Data Fig. 1A**). Consistent with
101 observations made in the parent clinical trial⁷, within the POIT-treated group, D+R+ participants
102 were significantly younger compared to those within the two other outcome groups (D+R- and
103 D-R-; **Extended Data Fig. 1B**). These data indicate that the subset of participants used in the
104 current study is representative of the overall trial population. To identify potential confounding
105 factors in our study, we initially examined relationships between variables captured in the study
106 population and 16S rRNA sequencing-based gut microbiota profiles generated on all available
107 longitudinally collected fecal samples (n=277 [Placebo, n=87; POIT, n=190] following quality
108 filtering and rarefaction; see methods section for details). As expected, bacterial community α -
109 diversity (number of taxa and their distribution) increased with advancing participant age at
110 screening (Pearson's correlation, $r=0.42$, $P<0.0001$; **Extended Data Fig. 1C**). To identify other
111 potential confounding factors, clinical and demographic variables were examined as independent
112 terms at each time point using *PERMANOVA* based on an unweighted UniFrac distance matrix.
113 Importantly, POIT outcomes ($P=0.008$, $R^2=0.07$, $n=47$) and specifically remission outcome
114 ($P=0.003$, $R^2=0.04$, $n=47$) related to variance in gut microbiota composition only at baseline prior
115 to POIT initiation, suggesting that gut microbiome composition prior to treatment associates with
116 clinical outcomes. Additionally, age at screening, sample collection date, sex, and study site
117 location significantly related to variance in gut microbiota composition at various time points
118 throughout the trial (**Table S3**). Thus, subsequent statistical analyses performed were adjusted
119 for these covariates (see method section for details).

120

121

122 **Children who develop POIT-induced remission exhibit a distinct gut microbiome** 123 **throughout the course of the trial.**

124

125 Comparing bacterial phylogenetic diversity (α -diversity) and composition (β -diversity) over
126 time revealed no significant difference between the POIT and placebo arms at any time point
127 (**Extended Data Fig. 1D and 1E**), indicating that POIT does not appreciably alter fecal microbiota
128 composition. However, within the POIT-treated group, the three distinct outcome groups exhibited
129 significant differences in fecal microbiota α - (**Fig. 1B**) and β -diversity that were evident at baseline
130 and sustained throughout the course of the trial ($P<0.001$, $R^2=0.029$, $n=127$, Linear Mixed Effect;
131 **Fig. 1C**). Specifically, the D+R+ group exhibited significantly lower α -diversity compared to D+R-

132 and D-R- groups ($P=0.001$ and 0.052 , respectively; Wilcoxon rank-sum test); this finding
133 remained significant following adjustment for age ($P=0.043$ ANOVA; **Fig. 1B and Extended Data**
134 **Fig. 1F and G**). Additionally, throughout the course of the trial, participants who achieved
135 remission (D+R+) exhibited significant differences in gut microbiota composition along the first
136 principal component (axis 1) compared to those who did not (D+R+ vs D+R-, $P=0.03$; D+R+ vs
137 D-R-, $P=0.003$, Linear Mixed Effect; **Fig. 1C**). This provided evidence that both gut microbiota
138 composition and diversity are associated with POIT outcomes within the trial participants.

139
140 In the parent IMPACT trial, baseline concentrations of peanut-specific serum
141 Immunoglobulin E (IgE) were predictive of remission⁷. We thus determined whether fecal
142 microbiota features related to IgE levels in POIT-treated children. In age-adjusted analyses,
143 significant positive correlations between α -diversity and serum levels of total IgE (**Fig. 1D**),
144 peanut-specific IgE (**Fig. 1E**) and Ara h 2-specific IgE (**Fig. 1F**; $P<0.05$ Pearson correlation for
145 all) were observed, suggesting that increased fecal diversity relates to higher IgE levels that are
146 associated with reduced likelihood of remission following POIT. Since both younger age and lower
147 baseline peanut-specific IgE levels predicted clinical remission in the IMPACT trial, we next
148 identified baseline bacterial Sequence Variances (SVs) associated with both peanut-specific IgE
149 level and remission status in age-adjusted analyses. *Romboutsia ilealis/timonensis* was
150 associated with POIT-induced remission, while *Ruminococcaceae* along with *Parabacteroides*
151 *distasonis*, and *Oscillospirales* members were associated with failure to develop remission
152 ($P.FDR<0.05$, generalized additive mix models, adjusted for age. **Fig. 1G**). *R. ilealis/timonensis*
153 was also negatively associated with peanut-specific IgE levels at baseline ($P.FDR<0.05$,
154 generalized additive mix models, adjusted for age. **Table S4 & Fig. 1H**) and with all component-
155 specific Ara h-specific IgEs (Ara h 1, 2, 3 and 6 IgEs; **Extended Data Fig. 1H**). However, no
156 significant difference in relative abundance of any SVs was observed when longitudinal analyses
157 were performed to determine whether these findings in baseline samples were sustained through
158 the course of the trial. Thus, 16S rRNA-based microbiota profiling provided initial evidence that
159 gut microbiota phylogenetic diversity and composition prior to POIT initiation relate to treatment
160 outcomes, and that the abundance of select gut microbial members associate with multiple
161 measures of peanut allergic sensitization irrespective of participant age.

162 **Baseline bile acid profile associates with POIT efficacy outcomes**

163
164
165 Distinct early-life fecal microbiome compositions associate with subsequent allergic
166 disease development and exhibit discrete metabolic profiles that can induce allergic inflammation
167 *in vitro*¹¹. Additionally, relationships between fecal metabolite profile and food allergy have been
168 previously described in humans¹²⁻¹⁵ and gut microbiomes are known to modulate host immunity
169 through the production of metabolites, including those that can affect immunotherapy efficacy^{16,17}.
170 To determine whether the distinct fecal microbiota compositions associated with POIT outcomes
171 exhibited divergent metabolic profiles, untargeted metabolomic analyses was performed on fecal
172 samples collected at baseline, end of treatment, and end of avoidance from study participants
173 ($n=58$ samples per visit) with sufficient available remaining sample for analysis at all three time
174 points (**Table S1 and Fig. 1A**). Like gut microbiota composition, baseline fecal metabolite profile

175 was associated with POIT outcome groups ($n=43$, $R^2=0.07$, $P=0.01$), and with remission status
176 ($n=43$, $R^2=0.04$, $P=0.01$; *PERMANOVA*, Euclidean distance matrix, **Supplementary Table S5**).

177
178 To identify metabolites that relate to POIT outcomes, a data reduction approach, weighted
179 gene correlation network analyses (WGCNA), was applied to identify modules of co-associated
180 metabolites which were then related to POIT outcomes. Fifty metabolite modules (Untargeted
181 Metabolite Modules [UMMs]; **Table S6**) were identified, 16 of which associated with POIT
182 outcomes at baseline, end of treatment, or end of avoidance ($P<0.05$ ANOVA, adjusted for age;
183 **Fig. 2A**). The majority of the outcome associated metabolic modules at baseline were elevated
184 in those who did not achieve remission (**Extended Data Fig. 2A**) and included multiple lipid-
185 containing modules, in particular bile acid and amino acid containing modules that distinguished
186 D+R+ from D+R- and D-R- groups (**Fig. 2A**). Further supporting these observations, bile acid
187 profiles significantly differed between POIT-outcome groups at baseline (**Fig. 2B**; $n=43$, $R^2=0.10$,
188 $P=0.015$, *PERMANOVA* Euclidean distance matrix), but not at the end of treatment or avoidance
189 (**Extended Data Fig. 2B**), suggesting that the specific profile of bile acids present at the initiation
190 of POIT influences treatment outcomes.

191
192 At baseline, two modules (UMM10 and UMM15) comprised primarily of unconjugated or
193 conjugated secondary bile acids respectively, exhibited opposing relationships with POIT-induced
194 remission (**Fig. 2C & Fig. 2D**). The module of unconjugated bile acids i.e. those lacking amino
195 acid conjugates, was increased in those who did not achieve POIT-induced remission (**Fig. 2F**).
196 A distinct group of secondary bile acids from UMM15 (**Fig. 2G**) and UMM4 (**Fig. 2E & Fig. 2H**)
197 including tauroursodeoxycholic acid sulfate, glycooursodeoxycholic acid sulfate and
198 tauroolithocholate 3-sulfate were depleted in the feces of children who did not develop remission.
199 Bile acids, produced by the liver are transformed into secondary bile acids exclusively by the gut
200 microbiome¹⁸. They play crucial roles in dietary lipid absorption, regulation of lipid, glucose and
201 xenobiotic metabolism¹⁹ and protect against bacterial overgrowth¹⁸. The secondary bile acids
202 enriched in those who achieved remission are known to have anti-inflammatory properties and in
203 the case of tauroolithocholate, capable of down-regulating macrophage inflammatory response to
204 antigenic stimulation²⁰.

205
206 Since bile acids are drivers of gut microbiota maturation in early life^{21,22}, we next
207 investigated whether relationships existed between the bile acid modules UMM10 and UMM15
208 and gut microbiota features that associated with POIT outcomes. Specifically, the eigenvector (a
209 measure of the joint abundance profile of a specific module) of UMM15, primarily comprised of
210 bacterial-derived secondary bile acids (**Supplementary Table S6**), exhibited a significant
211 negative relationship with fecal microbiota α -diversity (lower baseline α -diversity is associated
212 with POIT-mediated remission; **Fig. 1B**) and a positive correlation with axis 1 of the baseline
213 microbiota composition. In contrast the unconjugated bile acid module (UMM10) exhibited the
214 opposite relationship, being positively correlated with fecal α -diversity and negatively correlated
215 with axis 1 of the baseline microbiota composition (**Extended Data Fig. 2C**). These data suggest
216 that at baseline, secondary bile acids associate with the lower gut bacterial diversity (**Fig. 1B**) and
217 a distinct gut bacterial composition (**Fig. 1C**) that characterize children who develop POIT-induced
218 remission.

219

220 Notably, bile acid modules that differentiated POIT outcome groups at baseline were not
221 associated with clinical outcomes at the end of treatment or avoidance samples (**Fig. 2A**).
222 Nonetheless, we rationalized that specific bile acids within these modules may continue to
223 differentiate outcome groups at later time points. Leveraging generalized additive mixed models
224 on longitudinal metabolomics samples, the UMM10 unconjugated bile acid, glycodeoxycholate
225 was found to be in significantly higher concentrations in the feces of children for whom POIT-
226 failed to induce remission throughout the course of the trial ($P=0.021$; **Supplementary Table S8**).
227 Notably, glycodeoxycholate promotes innate lymphoid cell 3 secretion of IL-22²³, which can
228 reduce systemic absorption of peanut allergens by increasing intestinal barrier integrity, resulting
229 in reduced antigen presenting cell encounters with peanut antigens²⁴. These data indicate that
230 significant differences in bile acid profiles exist between POIT outcome groups, particularly in
231 baseline samples, and that glycodeoxycholate, which is known to reduce antigen exposure
232 remains significantly elevated over time in the feces of those who fail to achieve remission
233 following POIT treatment.

234

235 **Fecal microbiomes of non-remitting patients exhibit increased gluconeogenesis,** 236 **anaerobic energy metabolism and amino acid metabolism**

237

238 To investigate gut microbial pathways associated with POIT outcomes, shotgun
239 metagenomic sequencing was performed on baseline (n=76) end of treatment, (n=54), and end
240 of avoidance (n=55) samples (**Fig. 1A**), including all samples that had undergone parallel
241 untargeted metabolomic analysis. Application of WGCNA to shotgun metagenomic data identified
242 45 shotgun metagenomic modules (SMMs; **Supplementary Table S9**), seven of which
243 significantly associated with POIT outcomes (four at baseline and three at end of treatment
244 (**Fig. 3A**, ANOVA, $P<0.05$, adjusted for age). At baseline, POIT-associated shotgun metagenome
245 modules (SMMs) were primarily related to microbial growth (SMM6), energy metabolism
246 (SMM26), peptidoglycan (SSM10), and phospholipid biosynthesis (SMM11), while at the end of
247 treatment, long chain fatty acid production (SMM33) and gluconeogenesis and anaerobic energy
248 metabolism (SMM43) differed across the three outcome groups ($P<0.05$, ANOVA, adjusted for
249 age; **Fig. 3A**).

250

251 The gluconeogenesis and anaerobic energy metabolism module (SMM43), which was
252 enriched in children who failed to develop POIT-induced remission at the end of avoidance
253 (**Extended Data Fig. 2E**), was significantly correlated with 12 of the 16 metabolite modules
254 (module eigengenes) associated with POIT outcomes (Pearson correlation, $P<0.05$; **Fig. 3B**). This
255 included a positive correlation with the module of unconjugated bile acids (UMM10) and negative
256 correlations with the secondary bile acid module (UMM15) and three remission-associated amino
257 acid modules (UMM4, UMM5, and UMM43; **Fig. 3B**) that were decreased in non-responders
258 (**Extended Data Fig. 2D**). These data provide evidence that a fecal microbiome primarily
259 engaged in alternate pathways of glucose production from non-carbohydrate sources and
260 anaerobic metabolism contributes to the observed bile acid deconjugation and amino acid
261 depletion in participants who fail to achieve POIT-induced remission.

262

263 To validate these observations, we performed a secondary, integrative data analysis on
264 longitudinal metagenomic and paired metabolomic datasets using Multi-Omics Factor Analyses
265 (MOFA2) which identified seven distinct factors (**Extended Data Fig. 3A**), five of which
266 significantly differentiated POIT response groups (ANOVA, $P < 0.05$; **Fig. 3C & Extended Data**
267 **Fig. 3B**). Consistent with our findings, several of these factors included microbial pathways for
268 amino acid biosynthesis that were enriched in those who achieved POIT-induced remission. One
269 factor (Factor 2) included Gluconeogenesis and Anaerobic Energy Metabolism amongst the top
270 five microbial pathways within this factor (**Fig. 3C, Extended Data Fig. 3C**), which were enriched
271 in the fecal microbiome of children who did not develop POIT-induced remission (**Extended Data**
272 **Fig. 3B**). In addition, secondary bile acid metabolites including 7-ketodeoxycholate, 7-
273 ketolithocholate, chenodeoxycholate were amongst the top 5 metabolites in Factor 2, all of which
274 were depleted in the no remission group (**Fig. 3E**). Together, these data validate that microbial
275 gluconeogenesis and anaerobic metabolism relates with changes in the profile of secondary bile
276 and amino acids that associate with POIT efficacy.

277
278 To assess whether the top five secondary bile acids from Factor 2, which were all
279 increased in the remission groups at baseline, could serve as a predictive marker for POIT-
280 induced remission, a machine learning approach with logistic regression model was employed.
281 The baseline abundance of these five metabolites produced a moderate predictive ability (area
282 under the curve (AUC) from 100 times repeated five-fold cross-validation, measured as mean
283 $AUC \pm$ standard deviation (s.d.: $AUC_{\text{logistic_regression}}: 0.712 \pm 0.081$; **Fig. 3F**). To confirm our findings,
284 a second machine learning model with random forest was employed and demonstrated similar
285 performance (**Extended Data Fig. 3E**).

286 287 **Enhanced Microbiome Amino Acid Metabolism Associates with Failure to Induce** 288 **Remission.**

289
290 At the end of avoidance, the majority of POIT-associated metabolite modules (five out of
291 eight) were primarily comprised of amino acids (**Fig. 2A, Supplementary Table S6**). Several of
292 these (UMM4, 5, 17 and 42) were decreased in children for whom POIT failed to induce
293 desensitization and remission (D-R-; **Extended Data Fig. 2D**). Notably, amino acid profiles were
294 significantly different among POIT outcome groups at baseline ($n=43$, $R^2 = 0.08$; $P = 0.006$; **Fig.**
295 **4A**) and end of avoidance ($n=43$, $R^2 = 0.07$; $P = 0.039$, **Fig. 4B**), but not at the end of treatment
296 (*PERMANOVA* analyses, **Extended Data Fig. 3F**), suggesting that differences in dietary amino
297 acid intake and/or microbial amino acid metabolism differentiate those who do or do not develop
298 remission in response to POIT.

299
300 Moreover, at end of avoidance, POIT response-associated metabolite modules contained
301 a total of 117 amino acids and their derivatives, 68 of these belonged to UMM4 (**Table S6**), which
302 was significantly reduced in the D-R- group (**Extended Data Fig. 2D**). The majority of these amino
303 acid metabolites' abundances were decreased in relative concentration in the feces of children
304 who failed to achieve remission (**Fig. 4C**) Notably, increased concentrations of microbial-derived
305 branched-chain amino acid fermentation end products such as skatol and indole²⁵ were evident
306 in both the D+R- and D-R- groups (**Fig. 4C**) indicating that the observed reduction in amino acid

307 concentrations is due to increased microbial amino acid utilization capacity in those who failed to
308 achieve POIT-induced remission.

309
310 Amino acids represent a major energy source for anaerobic gut bacteria²⁶, and select
311 microbes are capable of harvesting amino acids by deconjugating primary bile acids²⁷. Decreased
312 fecal amino acid concentrations and increased anaerobic energy and gluconeogenesis
313 metabolism in POIT-treated children who failed to achieve remission prompted us to investigate
314 whether their gut microbiomes encoded a distinct or enhanced capacity for amino acid utilization.
315 Using generalized additive mixed models on longitudinal microbial pathway abundance data, we
316 found that the microbial pathways associated with amino acid metabolism including L-histidine
317 degradation, anerobic energy metabolism, L-citrulline biosynthesis (Arginine degradation), and
318 gluconeogenesis (which uses non carbohydrate sources, including amino acids for energy
319 production²⁸) were enriched in the gut microbiomes of children who did not achieve remission. In
320 contrast, and consistent with metabolite modules associated with remission, D+R+ children
321 possessed fecal microbiota that encoded pathways involved in amino acid biosynthesis
322 (generalized additive mix model, $P < 0.05$, but $P.FDR > 0.05$; **Fig. 4D & Table S8**). These data
323 indicate that gut microbiomes with enhanced capacity for gluconeogenesis and amino acid
324 metabolism, result in depletion of immunomodulatory amino and secondary bile acids that
325 associate with POIT failure.

326
327 Because peanut antigen exposure is critical to develop immunological tolerance to
328 peanut^{3,29} and children who failed to achieve remission exhibited a gut microbiome with enhanced
329 capacity for amino acid metabolism (**Fig. 4D**), we hypothesized that their gut microbiome may
330 also have increased capacity for peanut metabolism, effectively reducing available antigen. To
331 test this, stabilized *in vitro* fecal microbiome cultures from participants in each of the outcome
332 groups (D+R+, n=12, D+R-, n=12, D-R-, n=12) were developed as previously described³⁰ and co-
333 incubated with peanut extract under anaerobic conditions prior to Ara h 2 quantification by ELISA.
334 Fecal microbiomes of all participants, regardless of remission outcome, exhibited the capacity to
335 metabolize Ara h 2 peptides, one of the most proteolysis-resistant peanut protein antigens³¹.
336 However, the microbiome of those who failed to achieve remission exhibited a significantly
337 increased capacity to metabolize Ara h 2 peptides compared to those who achieved remission,
338 indicating that enhanced microbial metabolism of allergenic peanut peptides associates with POIT
339 failure (**Fig 4E**).

340 341 **Discussion**

342
343 Integrated analyses of 16S rRNA data generated from fecal samples longitudinally
344 collected from IMPACT participants (Placebo, n=87; POIT, n=190) provide evidence that
345 microbial activities in the fecal microbiome prior to POIT initiation relate to treatment outcomes.
346 The data also indicate that the composition of the gut microbiome is distinct over a three-year
347 treatment period in those who do or do not experience peanut allergy remission following POIT,
348 suggesting that microbial-mediated changes in immune function are associated with distinct
349 trajectories of microbiome development and POIT outcomes in study participants. Functional
350 analyses of fecal microbiomes indicate that bile acids, specifically secondary bile acids enriched

351 in baseline samples, associate with POIT-induced remission. Microbial-derived secondary bile
352 acids serve as hormones that regulate cholesterol metabolism and influence energy balance via
353 nuclear and G-protein-coupled receptors^{32,33} that also shape innate immune response^{34,35}.
354 Studies have demonstrated that the bile acid pool regulates colonic FOXP3+ regulatory T (Treg)
355 cells that express the transcription factor ROR γ ³⁶. Bile acids found to be increased in baseline
356 samples of participants who experienced peanut allergy remission in our study are known to have
357 allergy protective effects; for example, tauroursodeoxycholic acid attenuates allergic inflammation
358 by inhibiting unfolded protein response transducers³⁷.

359
360 Children for whom POIT failed to induce remission exhibit a significantly distinct gut
361 microbiome, enhanced for gluconeogenesis and anaerobic metabolism, indicating that these gut
362 microbiomes derive energy from alternative non-carbohydrate substrates. Our data indicate that
363 the gut microbiome of these children is enhanced for amino acid metabolism. Evidence for this
364 comes from the increased pools of deconjugated (primary) bile acids and a significant depletion
365 of secondary bile and amino acids in the feces of these children. Primary bile acids are most
366 commonly conjugated to the amino acids glycine and taurine to produce glycocholic and
367 taurocholic acids respectively¹⁸, which are subsequently converted to immunoregulatory
368 secondary bile acids by colonic bacteria¹⁸. Primary bile acids, specifically chenodeoxycholic acid,
369 was recently shown to promote food sensitization via activation of a retinoic acid response
370 element in dendritic cells, to promote food allergen specific IgE and IgG1³⁸. Enhanced colonic
371 microbial capacity to harvest amino acids from conjugated bile acids results in increased
372 concentrations of the deconjugated forms, essentially reverting them back to their primary bile
373 acid state. Thus, our findings indicate that a gut microbiome that primarily derives energy from
374 amino acid fermentation results in the depletion of immunomodulatory amino and secondary bile
375 acids both of which associate with POIT remission failure.

376
377 It is well established that peanut allergen exposure is critical to build tolerance and prevent
378 allergy development³. Our data suggests that a second microbial-derived mechanism of POIT
379 failure appears to involve reduced peanut antigen exposure. Food allergies and intolerances are
380 typically driven by specific protein motifs in foods such as Ara h peptides in peanuts, casein and
381 beta-lactoglobulin in cow's milk and tropomyosin proteins in shellfish³⁹. Ingested allergens
382 typically undergo enzymatic breakdown in the oral cavity, stomach, and small intestine⁴⁰ prior to
383 interacting with antigen-presenting cells⁴¹. However, certain key antigenic peanut peptides e.g.
384 Ara h 2 peptides, are highly resistant to proteolysis⁴², making it likely that they survive transit
385 through the upper gastrointestinal tract to the distal colon. The extent of peanut protein digestion
386 determines the concentrations and profile of antigenic peptides available for presentation by
387 antigen presenting cells. Our data indicates clear differences in amino acid metabolism capacity
388 and peanut degradation in participants who did or did not achieve remission suggesting that
389 differences in distal gut microbial protein catabolism may impact the quantity and profile of
390 antigenic peanut peptides available to promote tolerance development.

391
392 Gut microbial protein metabolism has never been explored in the context of food allergy,
393 particularly related to treatment-induced efficacy outcomes. Elucidating the impact of gut
394 microorganisms on allergic food proteins may pave the way to develop more effective

395 immunotherapeutic approaches either by targeting gut microbiome functions or by protecting
396 immunotherapeutic peanut proteins from microbial metabolism by encapsulating them in food-
397 grade colloidal systems. A similar encapsulation system for gluten immunotherapy is currently
398 being tested in several clinical trials^{43,44}, which so far have demonstrated safety and efficacy. Our
399 study highlights the potential role of the gut microbiome in POIT efficacy outcomes and suggests
400 that it could serve as both a prognostic biomarker to identify those for whom POIT may be most
401 successful and as a therapeutic target to improve rates of POIT-induced remission.

402

403

404 **Materials and Methods**

405

406 **Clinical trial description and study population**

407

408 Full details of the IMPACT clinical trial (NCT01867671) have been previously described⁴⁵.

409

410 **Sample collection, DNA extraction, 16S rRNA library preparation and sequencing**

411

412 Stool samples were collected from participants at home and stored at clinical collection
413 sites at -80 °C. Three hundred twenty-seven samples (n=327) were shipped to the University of
414 California San Francisco (UCSF), on dry ice, where they were also stored at -80 °C until
415 processed. Investigators of this study were blinded and did not have access to the metadata until
416 initial 16S rRNA data generation. Thus, all 327 samples were included for 16S rRNA sequencing.
417 Three hundred two (302) samples generated 16S rRNA data since some samples failed PCR
418 amplification or did not pass quality filtering and rarefaction during 16S rRNA analyses. Two
419 hundred seventy-seven (277) out of 302 samples belonged to participants that completed the
420 POIT trial until the end of the avoidance, and therefore, they were used in 16S rRNA data
421 analyses.

422

423 DNA was extracted from all stool samples using a modified cetyltrimethylammonium
424 bromide (CTAB) buffer extraction protocol as previously described^{11,46}. The variable region 4 (V4)
425 of the 16S rRNA gene was amplified using 1 ng μl^{-1} of DNA template using 515F and 806R primer
426 pairs as previously described⁴⁷. Amplicon concentrations were normalized using SequaPrep™
427 Normalization Plate Kit (ThermoFisher Scientific), quantified using the Qubit 2.0
428 Fluorometer and the dsDNA HS Assay Kit (Life Technologies) and pooled at 5 ng per sample
429 which was purified using AMPure SPRI beads (Beckman Coulter). 2 nM of library was spiked with
430 30% of PhiX control v3 (Illumina). The denatured libraries and PhiX were diluted to 20 pM, and
431 1.5 pM were loaded onto the Illumina NextSeq 500/550 v2.5 High Output cartridge.

432

433 Sequence data was processed as previously described⁴⁸. Forward and reverse reads
434 were demultiplexed by using Quantitative Insights Into Microbial Ecology (QIIME 1.9.1)⁴⁹.
435 Samples sequences with more than two bases having a Q-score less than 30 were truncated. As
436 recommended by the Divisive Amplicon Denoising Algorithm 2 (DADA2) v1.16 protocol in R with
437 the following modifications: Reads were maintained if they exhibited a maximum expected error
438 of two and a read length of at least 150 base pair (bp) using the *filterAndTrim* function in the *dada2*

439 package⁵⁰. Reads were dereplicated and errors were learned on 1×10^8 reads, from samples
440 chosen at random. Finally, chimeras were identified using the “consensus” method. Paired reads
441 were merged with a minimum overlap of 25 bp, and reads were aggregated into a count table.
442 Any V4 sequences abnormally short or long (± 5 bp from the most frequently observed bp length;
443 here: 253 bp) were also removed. We assigned taxonomic classifications to Sequence Variants
444 (SVs) using *assignTaxonomy* in the *dada2* package and an 80% bootstrap cutoff, utilizing the
445 SILVA v132 database⁵¹, and species identification with *assignSpecies* at 100% identity. All
446 species achieving an exact match were recorded, and the first in the list was used for descriptive
447 purposes. Once these steps were completed for each run, all runs were combined into a complete
448 SV table. A phylogenetic tree was constructed using *phangorn*^{52,53} and *DECIPHER* packages⁵⁴.
449 The SV table was then filtered only to variants belonging to the kingdom Bacteria. Variants were
450 also removed if they were present in less than 0.001% of the total number of observed sequences
451 reads. Next, we employed methods to remove potential contaminants based on SVs present in
452 negative controls. Specifically, SVs were removed if they were present in greater than 15% of the
453 negative controls and less than 15% of the samples⁴⁸ (primarily *Pseudomonas* SVs). For the
454 remaining sequence variants in negative controls, the mean of the read count for each was
455 calculated, rounded upward to the nearest whole number and subtracted for each of these SVs
456 in the dataset. Any remaining negative control SVs were subtracted from samples using the
457 maximum read count across negative controls. Data was representatively rarefied at 35,000 reads
458 per sample, a level selected to optimize sample count and community coverage.

459 460 **Metagenomic processing and data analysis**

461
462 One-hundred eighty-five samples (n=76 Baseline, n=54 EoT, n=55 EoA, **Fig. 1A**), were
463 chosen among the DNA samples extracted for 16S rRNA sequencing including samples that went
464 through untargeted metabolomic analyses. Fecal samples selected had sufficient remaining
465 material for paired metagenomic and metabolomic profiling. Extracted DNA was sent to the
466 Omega Bioservices Sequencing Laboratory (Norcross, GA, USA) for shotgun metagenome
467 sequencing. DNA concentration was measured using the QuantiFluor dsDNA System on a
468 Quantus Fluorometer (Promega, Madison, WI, USA). A Kapa Biosystems HyperPlus kit (Kapa
469 Biosystems, Wilmington, MA, USA) was used for library construction. Briefly, 50 ng of genomic
470 DNA was enzymatically sheared according to the manufacturer’s instructions. DNA fragment
471 ends were repaired, 3’ adenylated, and ligated to adapters. The resulting adapter-ligated libraries
472 were PCR-amplified. PCR product was cleaned up from the reaction mix with magnetic
473 beads. Then, Illumina libraries were quantified using the Qubit 2.0 Fluorometer with the dsDNA
474 High Sensitivity Assay Kit (Life Technologies, Grand Island, NY) and pooled at equal molar
475 concentrations. The final pooled libraries were submitted to the Center for Advanced Technology
476 (CAT) at the University of California San Francisco. The pooled libraries were sequenced using
477 the Illumina NovaSeq 6000 in a 2×150 bp paired-end run protocol targeting minimum 60,000,000
478 raw reads per sample in total.

479
480 Raw sequences from all lanes were merged into a concatenated file for each sample. Raw
481 FASTQ files underwent FASTQC⁵⁵ and quality and contaminant filtering using *bbTools* v38.73.
482 Specifically, *bbduk* trimmed Illumina adapters, removed any PhiX contamination, filtered low-

483 quality sequences, and employed trimming after a Q score less than 15 from both the 3' and 5'
484 directions. Finally, *bbmap* removed reads mapping to the human genome using GRCh38⁵⁶ as the
485 reference database. The median number of raw reads per sample was 97,502,238 (IQR
486 30,132,152). The median number of reads following Q15 quality trimming and filtering human
487 DNA using Bbduk v38.73 (<https://sourceforge.net/projects/bbmap/>) was 13,367,212 (IQR
488 2,073,330). All analyses were performed on quality-filtered reads. HUMAnN 3.0 pipeline was used
489 to identify genes⁵⁷, level4ECs and functional MetaCyc pathways from the short-reads, and to
490 normalize outputs into copies per million (CPM).

491

492 **Untargeted Metabolomics Analyses**

493

494 Among the samples that went through shotgun-metagenome analyses, 174 (n=58
495 Baseline, n=58 EoT, n=58 EoA, **Fig. 1A**) matching samples were available for untargeted
496 metabolomics analyses. Two hundred milligrams of stool per sample was submitted to Metabolon
497 Inc. (Durham, NC) for ultrahigh performance liquid chromatography/tandem mass spectrometry
498 (UPLC–MS/MS) and gas chromatography–mass spectrometry (GC–MS) using their standard
499 protocol (<http://www.metabolon.com/>). Briefly, samples were homogenized and subjected to
500 methanol extraction then split into aliquots for analysis by ultrahigh performance liquid
501 chromatography/mass spectrometry (UHPLC/MS) in the positive (two methods) and negative (two
502 methods) mode. Metabolites were then identified by automated comparison of ion features to a
503 reference library of chemical standards followed by visual inspection for quality control (as
504 previously described⁵⁸. Compounds were compared to Metabolon's in-house library of purified
505 standards, which includes more than 3,300 commercially available compounds. For statistical
506 analyses and data display, any missing values are assumed to be below the limits of detection;
507 these values were imputed with the compound minimum (minimum value imputation). For network
508 and statistical analyses, normalized, imputed, and log transformed area under curve dataset was
509 used.

510

511 ***In vitro* Fecal Microbiome Metabolism of Peanut**

512

513 Stool samples from IMPACT participants were prepared for culture as described
514 previously³⁰. Briefly, stool samples from 36 patients (D+R+, n=12, D+R-, n=12, D-R-, n=12) with
515 sufficient paired baseline and end of treatment material for the experiment were thawed on ice.
516 All fecal processing was completed under aerobic conditions. Stools were resuspended in Brain
517 Heart Infusion (BHI) media at a ratio of 10 ml/g stool prior to vigorous vortexing for 5 min and
518 filtering with a 50 µm cell strainer and storage at -80°C following 25% (volume/volume) glycerol
519 addition. A total of 10 µL of prepared feces was used to inoculate 1 mL of BHI medium
520 supplemented with 8 µL peanut extract (1/10 weight/volume in 50% glycerin, Hollister-Stier) and
521 incubated for 48 hours at 37°C under anaerobic conditions. Following 48 hours incubation,
522 microbiome cultures were centrifuged at 3,200 g for 10 min and filtered through 0.22 µm filters.
523 Ara h 2 peptide concentrations were determined using an Enzyme-Linked Immunosorbent Assay
524 (ELISA) according to manufacturer instructions (Indoor Biotechnologies, Charlottesville, VA).

525

526

527 **Statistical analyses**

528
529 Statistical analyses were performed in the R statistical programming language version
530 4.3.2. Phylogenetic diversity (Alpha diversity) was calculated in QIIME and was expressed as
531 Faith's phylogenetic diversity metric, using the *vegan* and *picante* packages in R. Wilcoxon tests
532 were calculated in R. For beta-diversity (microbiome composition), distance matrices based on
533 unweighted UniFrac for 16S rDNA data and Euclidian for metabolomics dataset were generated
534 using the *distance* function from *phyloseq* v1.30.0⁵⁹ and ordinated into two-dimensional space
535 using the *pcor* function from the *ape* v5.3 package⁶⁰. Permutational Analysis of Variance tests
536 (*PERMANOVA*; R^2 and P values) were generated for independent terms with 1000 permutations
537 using *adonis2* from the *vegan* package v2.5-6⁶¹. Pearson correlations and P values were
538 calculated and corrected for potential confounding factors such as age at screening, using the
539 *cor.test* function in R. When samples were used from multiple time points, for example, in Linear
540 Mix Effect (LME) models on longitudinal samples, only age was adjusted, and stated in figure
541 legends.

542 543 **Generalized Additive Mix Model**

544
545 Generalized Linear Mix Models were used on longitudinal microbiome data to determine
546 differences in microbial taxa, microbial pathways, metabolites between POIT outcome groups
547 (D+R+, D+R-, D-R-) and remission outcome (Yes or No), using Linear Model, Compound Poisson
548 Linear Model, Poisson, Negative Binomial, Zero-Inflated Negative Binomial, and Tweedie models
549 depending on data distribution. False-discovery corrections were made using the Benjamini-
550 Hochberg method.

551 552 **Weighted Gene Correlation Network Analyses**

553
554 Co-occurrence networks of microbial pathways and metabolites were constructed using
555 weighted correlation network analysis (WGCNA) with the R package *WGCNA*⁶² to find modules
556 of highly interconnected, mutually exclusive metabolites. Pearson correlations were used to
557 determine inter-metabolite and inter-microbial pathway relationships, where modules are
558 composed of positively correlated metabolites. We constructed a signed network using specific
559 parameters (power = 7, reassignThreshold = 0, mergeCutHeight = 0.25), by applying hierarchical
560 clustering and topology overlap measures (TOM). The minimum module size was set to five for
561 metabolomics and one for metagenomics data. Module eigengenes (MEs) were defined as the
562 first principal component of a given module and considered as a representative measure of the
563 joint abundance profile of that module. Each module eigengenes was used to test the association
564 between its respective module and POIT-outcomes using ANOVA. Module membership was used
565 to determine the interconnectedness of each metabolite or microbial pathways to its assigned
566 module and to identify "hub" metabolite or microbial pathways: this was defined as the correlation
567 between each metabolite or microbial pathways and the Module eigengenes (MEs) (strong
568 positive values indicate high interconnectedness) as previously described⁹.

569
570

571 **Multiomics Factor Analyses (MOFA2)**

572
573 MOFA uses multi-omics data from the same set of samples as input and generates a
574 model that infers a set of “Factors” that best explain patterns of covariation across samples⁶³.
575 Details of methodology can be found in the original publication⁶⁴. As input for the MOFA model,
576 we used untargeted metabolomics (1538 metabolites) and shotgun metagenomics datasets (518
577 features). All inputs were normalized by centralized log normalization. When fitting the model, we
578 selected for the top factors ordered by the mean fractional variance explained across omic
579 modalities (that is, factor 1 contributed the most, and factor 7 contributed the least to mean
580 fractional variation; **Extended Data Fig. 3A**). When testing factor values for statistically significant
581 differences between POIT outcome groups we used a two-tailed Mann–Whitney *U*-test.
582 **Extended Data Fig. 3B**). Top five features of metagenome and metabolome datasets from
583 significant factors were displayed (**Extended Data Fig. 3C**).

585 **Machine Learning Model with Logistic Regression and Random Forest**

586
587 For the predictive metabolite analysis, normalized abundance of top five metabolites from
588 Factor 2 of the MOFA2 analyses were processed with the mikropml R package ([https://CRAN.R-](https://CRAN.R-project.org/package=mikropml)
589 [project.org/package=mikropml](https://CRAN.R-project.org/package=mikropml))⁶⁵. We used Random Forest (rf) and Logistic Regression functions
590 (glmnet) with Remission (Yes versus No) as an outcome using 50% of the samples as training
591 set and 50% as the test set. Model performances were evaluated with repeated k-fold cross-
592 validation (tenfold, 10 repetitions) and parameters were tuned by choosing mtry and values
593 between 1 and the square root of the total number of variables. Model training was accomplished
594 with the caret R package (<https://topepo.github.io/caret/>), mtry and lambda values that determined
595 the highest model accuracy were chosen as input to Random Forest and Logistic Regression
596 analysis, respectively. Variable importance was assessed with permutations (100 iterations). Full
597 results are reported in **Supplementary Table S10**.

600 **Availability of data and materials**

601
602 The sequencing data generated from untargeted metabolomics, shotgun metagenomes
603 and amplicon sequencing for this study will be deposited to the NCBI SRA database. Additional
604 data can be shared upon request.

606 **Acknowledgements**

607
608 Research reported in this publication was supported by the National Institute of Allergy
609 and Infectious Diseases of the National Institutes of Health under Award Number UM1AI109565
610 and by the S.V.L's research program which is funded by AI128482, AI148104,
611 UM1AI160040 and AI089473. The content is solely the responsibility of the authors and does not
612 necessarily represent the official views of the National Institutes of Health. M.Ö. is supported by
613 postdoctoral T32 fellowship 2T32DK007762-46. We thank Rebecca L. Knoll, and Elad Deiss-

614 Yehiely for their internal review of this article. We also thank Immune Tolerance Network (ITN)
615 Leadership, IMPACT study team, and study participants for making this study possible.

616

617 **Author contributions**

618

619 Conceptualization, M.Ö. and S.V.L.; methodology, M.Ö., D.L.L., C.L.G., A.L., and S.V.L.;
620 data analysis, M.Ö.; investigation, M.Ö. D.L.L., C.L.G., A.L., L.M.W., C.B., S.S., S.M.J., and S.V.L
621 writing and editing original draft, M.Ö. and S.V.L.; writing review M.Ö., C.L.G., and S.V.L.; data
622 visualization, M.Ö., supervision, S.V.L., funding acquisition, S.V.L.

623

624 **Competing interests**

625

626 S.V.L is a board member and consultant for the biotechnology company Siolta
627 Therapeutics, Inc, and holds stock in the company. She also consults for Sanofi and for the Atria
628 Institute of New York. M.Ö. is supported in part by National Institute of Health Training Grant T32-
629 DK007762.

630

631 **Ethics Statement**

632


633 This study was approved by the Office of Human Research Ethics (OHRE), University of
634 North Carolina, Chapel Hill on April 9, 2013. The parent study titled, "IMPACT: Oral
635 Immunotherapy (OIT) for Induction of Tolerance and Desensitization in Peanut-Allergic was a
636 randomized, double-blind, placebo-controlled, multi-center study comparing peanut oral
637 immunotherapy (OIT) to placebo. Informed consent was obtained from a parent or guardian of all
638 participants.

639


640

641


642 **Figures and Figure Legends**




643
 644 **Figure 1. a**, Schematic overview of IMPACT trial fecal microbiome study⁹. **b**, At baseline, prior to
 645 POIT initiation, the D+R+ group exhibit significantly lower phylogenetic diversity (α -diversity)
 646 compared to either the D+R- and D-R- groups. Wilcoxon signed-rank test, $n=16$ (D+R+), 23
 647 (D+R-), and 8 (D-R-). **c**, The D+R+ group exhibit a significantly distinct gut microbiota composition
 648 compared with either the D+R- or D-R- groups throughout the IMPACT trial. Linear Mixed Effect
 649 Model ($P<0.05$, not significant when adjusted for age). **d**, **e**, **f**, Baseline gut bacterial phylogenetic
 650 diversity positively correlates with baseline total IgE, peanut-specific IgE, and Ara h 2-specific IgE
 651 levels, respectively. Pearson correlation, adjusted for age at screening. **g**, Baseline differentially
 652 abundant bacterial taxa between children who achieved remission versus no remission.
 653 Generalized Mixed Model ($P.FDR<0.05$, adjusted for age). **h**, Baseline Peanut-IgE associated
 654 bacterial taxa. Generalized Mixed Model ($P.FDR<0.05$). Error bars represent standard deviation.



655
656 **Figure 2. a**, Association between untargeted metabolomics module (UMM) eigengenes and POIT
657 outcomes (ANOVA, adjusted for age). **b**, Ordination of baseline secondary bile acid metabolites
658 ($n=43$, $R^2=0.10$; $P<0.015$, adjusted for age), PERMANOVA analyses based on Euclidian
659 dissimilarity metrics. **c**, Difference in baseline Module Eigengenes (ME), which were determined
660 based on WGCNA analyses (see Method Section) and represents a measure of the joint
661 abundance profile of a specific module, of UMM10, **d**, UMM15 Unconjugated BAs module, and **e**,
662 UMM4 between POIT-outcome groups (Wilcoxon signed-rank test). **f**, Z-scores of each bile acid-
663 related metabolites of UMM10, **g**, UMM15 and, **h**, UMM4 in each POIT-outcome groups (D+R+,
664 D+R-, and D-R-). Blue colors represent low z-scores thus low abundance and red colors represent
665 high z-score and higher abundance. Error bars represent standard deviation.




666
 667 **Figure 3. a**, Association between shotgun metagenomic module (SMM) eigengenes and POIT
 668 outcomes (ANOVA, adjusted for age). **b**, Heatmap showing Spearman correlation results
 669 between POIT-associated Untargeted Metabolomics Modules (UMMs) and Shotgun
 670 Metagenomics Modules (SMMs). Asterisk “*” represents $P < 0.05$, and double Asterisk “**”
 671 represents $P < 0.01$. **c**, Factor 2 from MOFA analyses is the most significantly differential Factor
 672 between POIT response groups and weighted significantly higher in no remission groups
 673 compared to D+R+ group ($P < 0.05$, Wilcoxon signed-rank test). **d**, Top 5 microbial pathways
 674 contributing the Factor 2 weight contains Gluconeogenesis and anaerobic energy metabolism
 675 pathways. **e**, Top 5 metabolites contributing the Factor 2 weight contains bile acid metabolites. **f**,
 676 The model’s predictive ability expressed as the AUC computed from 100 times repeated five-fold
 677 cross-validation. Blue line shows the average across the 100 times repeated five-fold cross-
 678 validations with the shaded area representing the 95% CI (mean AUC \pm standard deviation). The
 679 dashed diagonal line represents random chance. Error bars represent standard deviation.



680
 681 **Figure 4.** Fecal amino acid metabolite composition is distinct between POIT outcome groups at
 682 **a**, baseline ($n=43$, $R^2 = 0.08$; $P = 0.006$), and **b**, end of avoidance ($n=43$, $R^2 = 0.07$; $P = 0.039$).
 683 The colors representing the POIT outcome groups are as follows: green for D+R+, orange for
 684 D+R-, blue for D-R-. **c**, Z-scores of all amino acid metabolite abundance in eight modules-
 685 associated end of avoidance POIT outcome. **d**, Gut microbial pathways enriched in microbiome
 686 of children who developed remission (blue bars) versus no remission (orange bars). Generalized
 687 Mixed Models ($P < 0.05$, $P.FDR > 0.05$). **e**, Fecal microbiome of children who did not achieve POIT-
 688 induced remission have a higher capacity to metabolize peanut proteins compared to children
 689 who achieved POIT-induced remission (Wilcoxon signed-rank test). Data presented in this plot is
 690 the average of two independent experiment. Control group refers to BHI medium supplemented
 691 with peanut extract and incubated 48 h with other samples without the microbiome inoculation.
 692 Error bars represent standard deviation.
 693

694 **Extended Data**
695




697 **Extended Data Figure 1. a**, There was no significant difference in age between Placebo and
698 POIT groups at baseline (ANOVA, $P>0.05$). **b**, Participants who achieved POIT-induced
699 remission in the current study were significantly younger compared to participants in D+R- and
700 D-R- groups, similar to the original study (ANOVA, $P<0.05$). **c**, Phylogenetic diversity positively
701 correlates with participant age. ($P<0.05$; Pearson correlation). **d**, Phylogenetic diversity was
702 similar between Placebo and POIT arms throughout the IMPACT trial (*Linear Mix Model, adjusted*
703 *for age*). **e**, D+R+ has a lower bacterial phylogenetic diversity at baseline compared to D+R- and
704 D-R- groups ($P=0.043$, *Linear Mix Model, adjusted for age*). **f**, Gut bacterial composition is similar
705 between Placebo and POIT groups throughout the IMPACT trial (LME $n=277$; Placebo=87,
706 POIT=190). **g**, Gut bacterial composition is distinct between POIT outcome groups ($n=190$; D+R+
707 =54, D+R- =106, and D-R- =30; LME). **h**, Abundance of *Romboutsia ilealis* negatively correlates
708 with all measured peanut-specific and component specific IgE levels; Ara h 1, Ara h 2, Ara h 3,
709 and Ara h 6 (Pearson correlation, adjusted for age, $P<0.05$). LME: Linear Mix Effect. Error bars
710 represent standard deviation.

711

712

713

714




716 **Extended Data Figure 2. a**, Difference in baseline module eigengenes (ME) of POIT outcome-
717 associated untargeted metabolomics modules (Wilcoxon signed-rank test). **b**, Fecal bile acid
718 metabolite composition is not different between POIT-outcome groups at the end of treatment
719 and avoidance. Ordination of end of treatment and avoidance secondary bile acid metabolites,
720 *PERMANOVA* analyses based on Euclidian dissimilarity metrics ($P > 0.05$). **c**, The bile acid
721 modules (UMM10 and UMM15), which are significantly associated with POIT-outcome, correlate
722 with phylogenetic diversity and gut microbiome composition ($P < 0.05$, Pearson Correlation,
723 adjusted for age). **d**, Difference in end of treatment and avoidance module eigengenes (ME) of
724 POIT outcome-associated untargeted metabolomics modules (Wilcoxon signed-rank test). Error
725 bars represent standard deviation.

726

727

728

729



731 **Extended Data Figure 3. a**, MOFA2 analyses, variance explained by each omics datasets;
732 metabolomics and metagenomics. **b**, Seven MOFA2 factors were identified, five of which (Factors
733 1-5) were significantly different between POIT outcome groups ($P < 0.05$, (Wilcoxon signed-rank
734 test). **c**, Top five microbial pathways contributing to weight of each factor. **d**, Top five metabolites
735 contributing to weight of each factor. **e**, Comparison of average AUC between logistic regression
736 and random forest models in predicting remission outcome based on five metabolites from Factor
737 2. **f**, Fecal metabolite composition is not different between POIT outcome groups at the end of
738 avoidance (Euclidian distance matrix. $n=43$, $R^2 = 0.02$; $P = 0.25$). Orange and blue lollipop colors
739 represent negative and positive effect on factor weight, respectively. Error bars represent
740 standard deviation.

741

742

743

744 **References**

- 745 1 Lieberman, J. A. *et al.* The global burden of illness of peanut allergy: A comprehensive
746 literature review. *Allergy* **76**, 1367-1384 (2021). <https://doi.org/10.1111/all.14666>
747 2 Finkelman, F. D. Peanut allergy and anaphylaxis. *Curr Opin Immunol* **22**, 783-788 (2010).
748 <https://doi.org/10.1016/j.coi.2010.10.005>
749 3 Du Toit, G. *et al.* Randomized Trial of Peanut Consumption in Infants at Risk for Peanut
750 Allergy. *New Engl J Med* **372**, 803-813 (2015). <https://doi.org/10.1056/NEJMoa1414850>
751 4 Investigators, P. G. o. C. *et al.* AR101 Oral Immunotherapy for Peanut Allergy. *N Engl J*
752 *Med* **379**, 1991-2001 (2018). <https://doi.org/10.1056/NEJMoa1812856>
753 5 Wood, R. A. Food allergen immunotherapy: Current status and prospects for the future. *J*
754 *Allergy Clin Immunol* **137**, 973-982 (2016). <https://doi.org/10.1016/j.jaci.2016.01.001>
755 6 Blumchen, K. *et al.* Post hoc analysis examining symptom severity reduction and symptom
756 absence during food challenges in individuals who underwent oral immunotherapy for
757 peanut allergy: results from three trials. *Allergy Asthma Clin Immunol* **19**, 21 (2023).
758 <https://doi.org/10.1186/s13223-023-00757-8>
759 7 Jones, S. M. *et al.* Efficacy and safety of oral immunotherapy in children aged 1-3 years
760 with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-
761 controlled study. *Lancet* **399**, 359-371 (2022). [https://doi.org/10.1016/S0140-](https://doi.org/10.1016/S0140-6736(21)02390-4)
762 [6736\(21\)02390-4](https://doi.org/10.1016/S0140-6736(21)02390-4)
763 8 Yatsunenko, T. *et al.* Human gut microbiome viewed across age and geography. *Nature*
764 **486**, 222-227 (2012). <https://doi.org/10.1038/nature11053>
765 9 Fujimura, K. E. *et al.* Neonatal gut microbiota associates with childhood multisensitized
766 atopy and T cell differentiation. *Nat Med* **22**, 1187-1191 (2016).
767 <https://doi.org/10.1038/nm.4176>
768 10 Ozcam, M. & Lynch, S. V. The gut-airway microbiome axis in health and respiratory
769 diseases. *Nat Rev Microbiol* (2024). <https://doi.org/10.1038/s41579-024-01048-8>
770 11 Fujimura, K. E. *et al.* Neonatal gut microbiota associates with childhood multisensitized
771 atopy and T cell differentiation. *Nat Med* **22**, 1187-1191 (2016).
772 <https://doi.org/10.1038/nm.4176>
773 12 Bao, R. Y. *et al.* Fecal microbiome and metabolome differ in healthy and food-allergic
774 twins. *J Clin Invest* **131** (2021). [https://doi.org:ARTN e141935.10.1172/JCI141935](https://doi.org/ARTN e141935.10.1172/JCI141935)
775 13 Hong, X. *et al.* Metabolomic profiles during early childhood and risk of food allergies and
776 asthma in multiethnic children from a prospective birth cohort. *J Allergy Clin Immunol*
777 (2024). <https://doi.org/10.1016/j.jaci.2024.02.024>
778 14 Crestani, E. *et al.* Untargeted metabolomic profiling identifies disease-specific signatures
779 in food allergy and asthma. *J Allergy Clin Immunol* **145**, 897-906 (2020).
780 <https://doi.org/10.1016/j.jaci.2019.10.014>
781 15 Lee-Sarwar, K. A. *et al.* Early-life fecal metabolomics of food allergy. *Allergy* **78**, 512-521
782 (2023). <https://doi.org/10.1111/all.15602>
783 16 Routy, B. *et al.* Gut microbiome influences efficacy of PD-1-based immunotherapy against
784 epithelial tumors. *Science* **359**, 91-97 (2018). <https://doi.org/10.1126/science.aan3706>
785 17 Bjork, J. R. *et al.* Longitudinal gut microbiome changes in immune checkpoint blockade-
786 treated advanced melanoma. *Nat Med* **30**, 785-796 (2024).
787 <https://doi.org/10.1038/s41591-024-02803-3>
788 18 Collins, S. L., Stine, J. G., Bisanz, J. E., Okafor, C. D. & Patterson, A. D. Bile acids and
789 the gut microbiota: metabolic interactions and impacts on disease. *Nat Rev Microbiol* **21**,
790 236-247 (2023). <https://doi.org/10.1038/s41579-022-00805-x>
791 19 Rimal, B. *et al.* Bile salt hydrolase catalyses formation of amine-conjugated bile acids.
792 *Nature* **626**, 859-863 (2024). <https://doi.org/10.1038/s41586-023-06990-w>

- 793 20 Wammers, M. *et al.* Reprogramming of pro-inflammatory human macrophages to an anti-
794 inflammatory phenotype by bile acids. *Sci Rep* **8**, 255 (2018).
795 <https://doi.org/10.1038/s41598-017-18305-x>
- 796 21 van Best, N. *et al.* Bile acids drive the newborn's gut microbiota maturation. *Nat Commun*
797 **11** (2020). <https://doi.org/ARTN.3692.10.1038/s41467-020-17183-8>
- 798 22 Larabi, A. B., Masson, H. L. P. & Bäumlér, A. J. Bile acids as modulators of gut microbiota
799 composition and function. *Gut Microbes* **15** (2023). [https://doi.org/Artn](https://doi.org/Artn.2172671.10.1080/19490976.2023.2172671)
800 [2172671.10.1080/19490976.2023.2172671](https://doi.org/Artn.2172671.10.1080/19490976.2023.2172671)
- 801 23 Qi, X. *et al.* Gut microbiota-bile acid-interleukin-22 axis orchestrates polycystic ovary
802 syndrome. *Nat Med* **25**, 1225-1233 (2019). <https://doi.org/10.1038/s41591-019-0509-0>
- 803 24 Stefka, A. T. *et al.* Commensal bacteria protect against food allergen sensitization. *Proc*
804 *Natl Acad Sci U S A* **111**, 13145-13150 (2014). <https://doi.org/10.1073/pnas.1412008111>
- 805 25 Diether, N. E. & Willing, B. P. Microbial Fermentation of Dietary Protein: An Important
806 Factor in Diet-Microbe-Host Interaction. *Microorganisms* **7** (2019). [https://doi.org/ARTN](https://doi.org/ARTN.19.10.3390/microorganisms7010019)
807 [19.10.3390/microorganisms7010019](https://doi.org/ARTN.19.10.3390/microorganisms7010019)
- 808 26 Barker, H. A. Amino-Acid Degradation by Anaerobic-Bacteria. *Annu Rev Biochem* **50**, 23-
809 40 (1981). <https://doi.org/DOI.10.1146/annurev.bi.50.070181.000323>
- 810 27 Guzior, D. V. & Quinn, R. A. Review: microbial transformations of human bile acids.
811 *Microbiome* **9**, 140 (2021). <https://doi.org/10.1186/s40168-021-01101-1>
- 812 28 Brissac, T. *et al.* Gluconeogenesis, an essential metabolic pathway for pathogenic. *Mol*
813 *Microbiol* **98**, 518-534 (2015). <https://doi.org/10.1111/mmi.13139>
- 814 29 Du Toit, G. *et al.* Effect of Avoidance on Peanut Allergy after Early Peanut Consumption.
815 *New Engl J Med* **374**, 1435-1443 (2016). <https://doi.org/10.1056/NEJMoa1514209>
- 816 30 Spanogiannopoulos, P. *et al.* Host and gut bacteria share metabolic pathways for anti-
817 cancer drug metabolism. *Nat Microbiol* **7**, 1605-1620 (2022).
818 <https://doi.org/10.1038/s41564-022-01226-5>
- 819 31 Lehmann, K. *et al.* Structure and stability of 2S albumin-type peanut allergens::
820 implications for the severity of peanut allergic reactions. *Biochem J* **395**, 463-472 (2006).
821 <https://doi.org/10.1042/Bj20051728>
- 822 32 Wahlström, A., Sayin, S. I., Marschall, H. U. & Bäckhed, F. Intestinal Crosstalk between
823 Bile Acids and Microbiota and Its Impact on Host Metabolism. *Cell Metab* **24**, 41-50 (2016).
824 <https://doi.org/10.1016/j.cmet.2016.05.005>
- 825 33 Fiorucci, S. & Distrutti, E. Bile Acid-Activated Receptors, Intestinal Microbiota, and the
826 Treatment of Metabolic Disorders. *Trends Mol Med* **21**, 702-714 (2015).
827 <https://doi.org/10.1016/j.molmed.2015.09.001>
- 828 34 Postler, T. S. & Ghosh, S. Understanding the Holobiont: How Microbial Metabolites Affect
829 Human Health and Shape the Immune System. *Cell Metab* **26**, 110-130 (2017).
830 <https://doi.org/10.1016/j.cmet.2017.05.008>
- 831 35 Brestoff, J. R. & Artis, D. Commensal bacteria at the interface of host metabolism and the
832 immune system. *Nat Immunol* **14**, 676-684 (2013). <https://doi.org/10.1038/ni.2640>
- 833 36 Song, X. Y. *et al.* Microbial bile acid metabolites modulate gut ROR γ . regulatory T cell
834 homeostasis. *Nature* **577**, 410-+ (2020). <https://doi.org/10.1038/s41586-019-1865-0>
- 835 37 Nakada, E. M. *et al.* Conjugated bile acids attenuate allergen-induced airway inflammation
836 and hyperresponsiveness by inhibiting UPR transducers. *JCI Insight* **4** (2019).
837 <https://doi.org/10.1172/jci.insight.98101>
- 838 38 Wu, R. L. *et al.* The bile acid-activated retinoic acid response in dendritic cells is involved
839 in food allergen sensitization. *Allergy* **77**, 483-498 (2022).
840 <https://doi.org/10.1111/all.15039>
- 841 39 Yu, W., Freeland, D. M. H. & Nadeau, K. C. Food allergy: immune mechanisms, diagnosis
842 and immunotherapy. *Nat Rev Immunol* **16**, 751-765 (2016).
843 <https://doi.org/10.1038/nri.2016.111>

- 844 40 Pekar, J., Ret, D. & Untersmayr, E. Stability of allergens. *Mol Immunol* **100**, 14-20 (2018).
845 <https://doi.org/10.1016/j.molimm.2018.03.017>
- 846 41 Koidl, L., Gentile, S. A. & Untersmayr, E. Allergen Stability in Food Allergy: A Clinician's
847 Perspective. *Curr Allergy Asthma Rep* **23**, 601-612 (2023).
848 <https://doi.org/10.1007/s11882-023-01107-9>
- 849 42 Hemmings, O., Du Toit, G., Radulovic, S., Lack, G. & Santos, A. F. Ara h 2 is the dominant
850 peanut allergen despite similarities with Ara h 6. *J Allergy Clin Immun* **146**, 621-+ (2020).
851 <https://doi.org/10.1016/j.jaci.2020.03.026>
- 852 43 Kelly, C. P. *et al.* TAK-101 Nanoparticles Induce Gluten-Specific Tolerance in Celiac
853 Disease: A Randomized, Double-Blind, Placebo-Controlled Study. *Gastroenterology* **161**,
854 66-+ (2021). <https://doi.org/10.1053/j.gastro.2021.03.014>
- 855 44 Benne, N., ter Braake, D., Stoppelenburg, A. J. & Broere, F. Nanoparticles for Inducing
856 Antigen-Specific T Cell Tolerance in Autoimmune Diseases. *Front Immunol* **13** (2022).
857 <https://doi.org/ARTN> 864403. 10.3389/fimmu.2022.864403
- 858 45 Jones, S. M. *et al.* Efficacy and safety of oral immunotherapy in children aged 1-3 years
859 with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-
860 controlled study. *Lancet* **399**, 359-371 (2022).
- 861 46 DeAngelis, K. M. *et al.* Selective progressive response of soil microbial community to wild
862 oat roots. *Isme J* **3**, 168-178 (2009). <https://doi.org/10.1038/ismej.2008.103>
- 863 47 Caporaso, J. G. *et al.* Global patterns of 16S rRNA diversity at a depth of millions of
864 sequences per sample. *P Natl Acad Sci USA* **108**, 4516-4522 (2011).
865 <https://doi.org/10.1073/pnas.1000080107>
- 866 48 McCauley, K. E. *et al.* Heritable vaginal bacteria influence immune tolerance and relate to
867 early-life markers of allergic sensitization in infancy. *Cell Rep Med* **3** (2022).
868 <https://doi.org/ARTN> 100713. 10.1016/j.xcrm.2022.100713
- 869 49 Kuczynski, J. *et al.* Using QIIME to analyze 16S rRNA gene sequences from microbial
870 communities. *Curr Protoc Microbiol* **Chapter 1**, Unit 1E 5 (2012).
871 <https://doi.org/10.1002/9780471729259.mc01e05s27>
- 872 50 Callahan, B. J. *et al.* DADA2: High-resolution sample inference from Illumina amplicon
873 data. *Nat Methods* **13**, 581-583 (2016). <https://doi.org/10.1038/nmeth.3869>
- 874 51 Quast, C. *et al.* The SILVA ribosomal RNA gene database project: improved data
875 processing and web-based tools. *Nucleic Acids Res* **41**, D590-596 (2013).
876 <https://doi.org/10.1093/nar/gks1219>
- 877 52 Schliep, K. P. phangorn: phylogenetic analysis in R. *Bioinformatics* **27**, 592-593 (2011).
878 <https://doi.org/10.1093/bioinformatics/btq706>
- 879 53 Schliep, K., Potts, A. J., Morrison, D. A. & Grimm, G. W. Intertwining phylogenetic trees
880 and networks. *Methods Ecol Evol* **8**, 1212-1220 (2017). <https://doi.org/10.1111/2041-210x.12760>
- 881
- 882 54 Wright, E. S. Using DECIPHER v2.0 to Analyze Big Biological Sequence Data in R. *R J*
883 **8**, 352-359 (2016).
- 884 55 Davis, M. P. A., van Dongen, S., Abreu-Goodger, C., Bartonicek, N. & Enright, A. J.
885 Kraken: A set of tools for quality control and analysis Of high-throughput sequence data.
886 *Methods* **63**, 41-49 (2013). <https://doi.org/10.1016/j.ymeth.2013.06.027>
- 887 56 Schneider, V. A. *et al.* Evaluation of GRCh38 and de novo haploid genome assemblies
888 demonstrates the enduring quality of the reference assembly. *Genome Res* **27**, 849-864
889 (2017). <https://doi.org/10.1101/gr.213611.116>
- 890 57 Beghini, F. *et al.* Integrating taxonomic, functional, and strain-level profiling of diverse
891 microbial communities with bioBakery 3. *Elife* **10** (2021). <https://doi.org/ARTN> e65088.
892 10.7554/eLife.65088

- 893 58 DeHaven, C. D., Evans, A. M., Dai, H. P. & Lawton, K. A. Organization of GC/MS and
894 LC/MS metabolomics data into chemical libraries. *J Cheminformatics* **2** (2010).
895 <https://doi.org:Artn> 9. 10.1186/1758-2946-2-9
- 896 59 McMurdie, P. J. & Holmes, S. phyloseq: An R Package for Reproducible Interactive
897 Analysis and Graphics of Microbiome Census Data. *Plos One* **8** (2013).
898 <https://doi.org:ARTN> e61217. 10.1371/journal.pone.0061217
- 899 60 Paradis, E. & Schliep, K. ape 5.0: an environment for modern phylogenetics and
900 evolutionary analyses in R. *Bioinformatics* **35**, 526-528 (2019).
901 <https://doi.org:10.1093/bioinformatics/bty633>
- 902 61 Dixon, P. VEGAN, a package of R functions for community ecology. *J Veg Sci* **14**, 927-
903 930 (2003). <https://doi.org:Doi> 10.1658/1100-9233(2003)014[0927:Vaporf]2.0.Co;2
- 904 62 Langfelder, P. & Horvath, S. WGCNA: an R package for weighted correlation network
905 analysis. *BMC Bioinformatics* **9**, 559 (2008). <https://doi.org:10.1186/1471-2105-9-559>
- 906 63 Thiele Orberg, E. *et al.* Bacteria and bacteriophage consortia are associated with
907 protective intestinal metabolites in patients receiving stem cell transplantation. *Nat Cancer*
908 **5**, 187-208 (2024). <https://doi.org:10.1038/s43018-023-00669-x>
- 909 64 Argelaguet, R. *et al.* Multi-Omics Factor Analysis-a framework for unsupervised integration
910 of multi-omics data sets. *Mol Syst Biol* **14**, e8124 (2018).
911 <https://doi.org:10.15252/msb.20178124>
- 912 65 Topcuoglu, B. D. *et al.* mikropml: User-Friendly R Package for Supervised Machine
913 Learning Pipelines. *J Open Source Softw* **6** (2021). <https://doi.org:10.21105/joss.03073>
- 914